Dynamic Response of Donor-Derived Cell-Free DNA Following Treatment of Acute Rejection in Kidney Allografts.

Background The quantification of rejection treatment efficacy has been insufficient using traditional markers due, in part, to the lagging response of serum creatinine and histologic alterations on biopsy specimens. Donor-derived cell-free DNA (dd-cfDNA) is a molecular marker of injury that may assess allograft injury after rejection. Methods Retrospective review of the DART study identified 70 patients who had a clinically indicated biopsy, simultaneous dd-cfDNA measurement, and at least one follow-up dd-cfDNA within 3 months post-treatment. Thirty-five patients had no biopsy-proven rejection and no rejection treatment (NR), 16 patients had no biopsy-proven rejection but did receive rejection treatment (CR), 9 patients had diagnosis of ABMR/mixed rejection on biopsy and received rejection treatment (ABMR), and 10 patients had diagnosis of TCMR and received rejection treatment (TCMR). The CR, ABMR, and TCMR groups combined to form a rejection (R) group. Results In the R group, median dd-cfDNA values at baseline and 1 month were 0.62% and 0.35% (n=21 pairs, p=0.34), and at baseline and 2-3 months were 0.77% and 0.21% (n=23 pairs, p=0.002). In TCMR, median dd-cfDNA values at baseline and 1 month were 1.13% and 0.37% (n=5 pairs, p=0.63), and at baseline and 2-3 months were 0.25% and 0.12% (n=9 pairs, p=0.004). In ABMR, median dd-cfDNA values at baseline and 1 month were 1.61% and 1.2 % (n=6 pairs, p>0.99), and at baseline and 2-3 months were 3.85% and 1.32% (n=6 pairs, p=0.09). In CR, median dd-cfDNA values at baseline and 1 month were 0.31% and 0.29% (n=10 pairs, p=0.38), and at baseline and 2-3 months were 0.38% and 0.17% (n=8 pairs, p=0.31). Lastly, in NR, median dd-cfDNA values at baseline and 1 month were 0.23% and 0.18% (n=21 pairs, p=0.10), and at baseline and 2-3 months were 0.33% and 0.17% (n=26 pairs, p=0.003). Changes in serum creatinine across 1 month and 2-3 months following rejection were similar. Conclusions dd-cfDNA may be a useful dynamic biomarker to assess the health of the kidney allograft following rejection treatment.

[1]  C. Thongprayoon,et al.  The Use of Donor-Derived Cell-Free DNA for Assessment of Allograft Rejection and Injury Status , 2020, Journal of clinical medicine.

[2]  J. Melancon,et al.  High levels of dd‐cfDNA identify patients with TCMR 1A and borderline allograft rejection at elevated risk of graft injury , 2020, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[3]  A. Chong,et al.  Outstanding questions in transplantation: B cells, alloantibodies, and humoral rejection , 2019, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[4]  M. Gillespie,et al.  Donor-derived Cell-free DNA May Confirm Real-time Response to Treatment of Acute Rejection in Renal Transplant Recipients. , 2019, Transplantation.

[5]  A. Thorne,et al.  Donor-specific Cell-free DNA as a Biomarker in Solid Organ Transplantation. A Systematic Review , 2019, Transplantation.

[6]  D. Abramowicz,et al.  Non-invasive Biomarkers of Acute Rejection in Kidney Transplantation: Novel Targets and Strategies , 2019, Front. Med..

[7]  J. Sninsky,et al.  Donor-derived Cell-free DNA Identifies Antibody-mediated Rejection in Donor Specific Antibody Positive Kidney Transplant Recipients , 2018, Transplantation direct.

[8]  J. Sninsky,et al.  Cell-Free DNA and Active Rejection in Kidney Allografts. , 2017, Journal of the American Society of Nephrology.

[9]  A. Zuckermann,et al.  Analysis of Donor-Derived Cell-Free DNA with 3-Year Outcomes in Heart Transplant Recipients , 2017 .

[10]  J. Sninsky,et al.  Biological Variation of Donor-Derived Cell-Free DNA in Renal Transplant Recipients: Clinical Implications. , 2017, The journal of applied laboratory medicine.

[11]  J. Cooper,et al.  Acute antibody-mediated rejection in kidney transplant recipients. , 2017, Transplantation reviews.

[12]  J. Sninsky,et al.  Validation of a Clinical-Grade Assay to Measure Donor-Derived Cell-Free DNA in Solid Organ Transplant Recipients. , 2016, The Journal of molecular diagnostics : JMD.

[13]  M. Haas,et al.  The Revised (2013) Banff Classification for Antibody‐Mediated Rejection of Renal Allografts: Update, Difficulties, and Future Considerations , 2016, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[14]  J. Gummert,et al.  Donor-Derived Cell-Free DNA Is a Novel Universal Biomarker for Allograft Rejection in Solid Organ Transplantation. , 2015, Transplantation proceedings.

[15]  Daniel Bernstein,et al.  Circulating Cell-Free DNA Enables Noninvasive Diagnosis of Heart Transplant Rejection , 2014, Science Translational Medicine.

[16]  S. Chadban,et al.  The Treatment of Acute Antibody-Mediated Rejection in Kidney Transplant Recipients—A Systematic Review , 2012, Transplantation.

[17]  J. Sellarésa,et al.  Understanding the Causes of Kidney Transplant Failure : The Dominant Role of Antibody-Mediated Rejection and Nonadherence , 2011 .